PDAC exhibits several tumor-specific antigens, such as carcinoembryonic antigen (CEA), mesothelin (MSLN), and mucin 1 (MUC1), which are promising determinants for CAR T cell therapy [226, 227]. This evidence concerns the gene CEACAM5 and neoplasm.